Organigram Global earnings date
Organigram Global (0OG) Q3 2026 Earnings Report
DE:0OG Q3 2026 EPS Results
- Actual EPS
- EUR 0.48
- Consensus EPS
- -EUR 0.01
- Beat/Miss
- Beat by +EUR 0.49
- One Year Ago EPS
- -EUR 0.03
DE:0OG Q3 2026 Revenue Results
- Actual Revenue
- EUR 67.23M
- Expected Revenue
- EUR 61.56M
- Beat/Miss
- Beat by +EUR 5.66M
- YoY Revenue Growth
- +49.43%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 08/11/2026
- Time
- Before Open
- Conference Call
- Tuesday, August 11, 2026
Organigram Global's next earnings date is estimated for December 22, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call communicated strong operational and financial momentum driven largely by the Sanity acquisition: record revenue, margin expansion, record adjusted EBITDA, and meaningful international diversification. Operational improvements in cultivation and category share gains in Canada reinforce the positive narrative. Key risks include negative free cash flow driven by working capital build, pending EU-GMP certification and tight EU-GMP supply into Germany, earlier vape/pre-roll quality issues in Canada, and U.S. regulatory uncertainty. Net income was materially boosted by non-cash fair value gains, so underlying cash generation and integration-related working capital remain focal concerns. On balance, the positive financial results, strategic diversification, and improving margin trajectory outweigh the liquidity and regulatory challenges discussed.
Management guided full‑year fiscal 2026 revenue to exceed $350 million, with adjusted gross margin and adjusted EBITDA expected to meaningfully exceed fiscal 2025 levels; they reiterated Sanity is expected to average ~EUR 25 million of quarterly revenue (Sanity delivered EUR 24.5M since April 15 and EUR 25.5M for the full quarter), international sales now constitute ~35% of consolidated revenue (vs ~10% pre‑acquisition), and they expect Q4 to outperform Q3. They cautioned that working‑capital investments tied to the Sanity integration will result in negative free cash flow for the full year (Q3 free cash flow was an outflow of $3.9M) but forecast positive free cash flow in Q4; Q3 results underpinning the outlook included record net revenue of $105.8M, adjusted gross margin of 37% (+300 bps YoY, +600 bps QoQ), record adjusted EBITDA of $13.4M, cash & equivalents of $11.7M and total liquidity of $49.2M. Management also noted Sanity margins are in line with expectations, Germany demand remains strong with minimal price compression, and that achieving EU‑GMP would meaningfully improve margins going forward.
- Record Quarterly Revenue and Accretive AcquisitionNet revenue of $105.8M, up 49% YoY from $70.8M. Contribution from Sanity Group: ~EUR 24.5M since acquisition (≈CAD $40M) and EUR 25.5M for the full quarter, in line with acquisition expectations.
- Adjusted Gross Margin ExpansionAdjusted gross margin improved to 37%, up 300 basis points year-over-year and 600 basis points sequentially, driven by Sanity contributions and Canadian operational improvements.
- Record Adjusted EBITDA and Improved ProfitabilityRecord adjusted EBITDA of $13.4M vs $5.7M prior year (+136% YoY). Company delivered positive net income of $105.5M vs a loss of $6.3M in the prior year period (note: major non-cash fair value gains contributed materially).
- Significant International DiversificationInternational revenues represented ~35% of consolidated revenue this quarter vs ~10% prior to the Sanity acquisition, materially diversifying revenue base and establishing a vertically integrated supply chain to Europe.
- Strong Category and SKU-Level Performance in CanadaOrganigram held 11.1% share of the Canadian recreational market. Flower share 12.5% (+2.0 percentage points YoY); concentrates #1 with 17.9% share (+3.3 ppts YoY); beverages 8.6% share (+3.1 ppts YoY, exiting June >10%). BOXHOT infused pre-rolls +0.8 ppts YoY. Vapes (all-in-one) +1.1 ppts MoM in June; infused pre-rolls +0.3 ppts MoM.
- Operational Cultivation ImprovementsMoncton average THC potency reached a record 30.4%. Harvested kilograms remained >30,000 per quarter, ~25% higher YoY. Company reduced SKU count by ~10% to simplify portfolio and improve efficiency.
- Improved Underlying Cash Generation (Before Working Capital)Cash provided by operating activities before working capital changes was $6.2M vs cash used of $0.7M prior year, reflecting stronger operating performance and improved mix.
- Clear Guidance and ConfidenceManagement expects fiscal 2026 revenue to exceed $350M and adjusted gross margin and adjusted EBITDA to meaningfully exceed FY2025 levels. Company expects positive free cash flow in Q4 despite full-year negative FCF guidance due to integration-related working capital.
DE:0OG Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Dec 22, 2026 | 2026 (Q4) | 0.01- | -0.18 | ― | ― |
| Aug 11, 2026 | 2026 (Q3) | -0.010.48 | -0.03 | 1618.00% (+0.51) | |
| May 12, 2026 | 2026 (Q2) | -0.01-0.01 | 0.2 | -103.13% (-0.21) | |
| Feb 10, 2026 | 2026 (Q1) | -0.010.09 | -0.13 | 173.00% (+0.22) | |
| Dec 16, 2025 | 2025 (Q4) | -0.00-0.18 | -0.03 | -526.67% (-0.15) | |
| Aug 13, 2025 | 2025 (Q3) | -0.01-0.03 | 0.02 | -278.57% (-0.05) | |
| May 12, 2025 | 2025 (Q2) | -0.020.20 | -0.14 | 240.97% (+0.35) | |
| Feb 11, 2025 | 2025 (Q1) | -0.02-0.13 | -0.11 | -14.29% (-0.02) | |
| Dec 18, 2024 | 2024 (Q4) | -0.02-0.03 | -0.26 | 88.92% (+0.23) | |
| Aug 13, 2024 | 2024 (Q3) | -0.040.02 | -1.69 | 101.06% (+1.70) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


